Invenra Inc., a leader in multispecific antibody discovery and development, today announced the launch of its B-Body Express™ Antibody Expression service. This new offering enables biotechnology and ...

Invenra Inc., a leader in multispecific antibody discovery and development, today announced the launch of its B-Body Expresstm Antibody Expression service. This new offering enables biotechnology and ...

This new offering enables biotechnology and pharmaceutical companies to rapidly access Invenra's premier B-Body® bispecific antibody platform, delivering high-purity, validated bispecific ...

Shares of biotech companies involved in the development of monoclonal antibody cancer therapies were moving all over the ...

Swiss oncology firm Veraxa Biotech is set to go public in the US through a merger with Voyager Acquisition Corp, a healthcare ...

AbTherx's antibody discovery platform is powered by Atlas Mice ... which enables native-like IgG bispecific antibodies that improve manufacturability and developability. This is accomplished ...

Market turmoil may have frozen the traditional IPO pipeline, but German antibody biotech Veraxa is turning to the special purpose acquisition company (SPAC) model to hop onto the Nasdaq. | Market ...

BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally ...